论文部分内容阅读
目的:探讨信号转导和转录活化因子(signal transducer and activator of transcription,STAT)-1在上皮性卵巢癌组织中的表达及其与预后的关系。方法:应用显微切割法从石蜡切片标本中提取mRNA,实时荧光定量PCR(real-time fluorogentic quantitative PCR,RFQ-PCR)和免疫组织化学方法检测105例原发性卵巢上皮癌和29例正常卵巢组织中STAT-1 mRNA及蛋白的表达,并分析其蛋白表达与预后的相关性。结果:上皮性卵巢癌组织中STAT-1 mRNA的表达高于正常卵巢组织[(0.96±1.05)vs(0.46±0.57),P=0.032],但mRNA表达水平与卵巢癌的手术分期、病理分级以及生存时间无关(P>0.05);上皮性卵巢癌组织中STAT-1和P-STAT-1蛋白的阳性表达率分别为72.4%和71.9%,显著高于正常卵巢组织(P<0.05),但蛋白表达水平与病理分级和手术分期无明显相关性(P>0.05)。在行辅助泰素化疗的病例组中STAT-1和P-STAT-1蛋白高表达患者的预后较好,总的生存时间长于低表达患者(P<0.05);STAT-1蛋白高表达的卵巢癌患者无瘤生存时间明显长于低表达患者(P<0.01)。结论:STAT-1在上皮性卵巢癌中存在异常表达,与紫杉醇类药物化疗后的预后密切相关。STAT-1可能是抑制肿瘤细胞生长的关键因子之一。
Objective: To investigate the expression of signal transducer and activator of transcription (STAT-1) in epithelial ovarian cancer and its relationship with prognosis. Methods: mRNA was extracted from paraffin sections by microdissection, and 105 cases of primary epithelial ovarian cancer and 29 cases of normal ovary were detected by real-time fluorogentic quantitative PCR (RFQ-PCR) and immunohistochemistry STAT-1 mRNA and protein expression, and analysis of its protein expression and prognosis. Results: The positive expression of STAT-1 mRNA in epithelial ovarian cancer tissues was significantly higher than that in normal ovarian tissues [(0.96 ± 1.05) vs (0.46 ± 0.57), P = 0.032] (P> 0.05). The positive rates of STAT-1 and P-STAT-1 in epithelial ovarian cancer tissues were 72.4% and 71.9% respectively, which were significantly higher than those in normal ovarian tissues (P <0.05) However, there was no significant correlation between protein expression and pathological grade and surgical stage (P> 0.05). The prognosis of patients with high expression of STAT-1 and P-STAT-1 protein was better in case group receiving TAX chemotherapy, and the total survival time was longer than that in low expression group (P <0.05). The ovarian tissue with high expression of STAT-1 protein Cancer-free survival time was significantly longer than patients with low expression (P <0.01). Conclusion: The abnormal expression of STAT-1 in epithelial ovarian cancer is closely related to the prognosis of paclitaxel after chemotherapy. STAT-1 may be one of the key factors inhibiting tumor cell growth.